Collins Helen Louise — SEC Form 4 filings
SEC reporting owner CIK 1701247. 19 Form 4 filings on record with FilingPulse; latest filed 2026-08-19.
Transaction summary — filings shown
Covers all 19 filings on record, filed 2024-02-15 to 2026-08-19. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 23 legs across 11 filings — 175,816 shares, $5,661,929 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 33.
- Largest priced transaction: sale of 40,000 shares @ $35.10 ($1,404,024) in Enliven Therapeutics, Inc., filed 2026-03-27.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | CHIEF MEDICAL OFFICER | 14 | — | 23 legs · 175,816 sh · $5,661,929 | 28 |
| Kura Oncology, Inc. (KURA) | Director | 3 | — | — | 3 |
| IO Biotech, Inc. (IOBT) | Director | 2 | — | — | 2 |
Form 4 filings — Collins Helen Louise
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,900 @ $58.37 · Sale (S): 1,100 @ $59.35 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-07-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 231 @ $50.05 · Sale (S): 459 @ $51.55 · Sale (S): 2,063 @ $52.39 · Sale (S): 2,184 @ $53.42 · Sale (S): 63 @ $53.92 · +1 more | EDGAR |
| 2026-06-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 1,268 @ $42.83 · Sale (S): 2,599 @ $43.87 · Sale (S): 1,133 @ $44.74 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 3,475 @ $39.53 · Sale (S): 1,302 @ $40.25 · Sale (S): 223 @ $41.21 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-04-21 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 140 @ $45.81 · Sale (S): 2,419 @ $47.39 · Sale (S): 2,441 @ $48.06 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-27 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 40,000 @ $2.48 · Sale (S): 40,000 @ $35.10 · Option exercise (M): 40,000 (derivative) @ $0 | EDGAR |
| 2026-03-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 5,000 @ $2.48 · Sale (S): 5,000 @ $27.76 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-03-11 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 29,871 @ $2.48 · Sale (S): 29,871 @ $30.02 · Option exercise (M): 10,129 @ $2.48 · Sale (S): 10,129 @ $30.19 · Option exercise (M): 29,871 (derivative) @ $0 · Option exercise (M): 10,129 (derivative) @ $0 | EDGAR |
| 2026-02-19 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 45,000 @ $2.48 · Sale (S): 45,000 @ $26.17 · Option exercise (M): 45,000 (derivative) @ $0 | EDGAR |
| 2026-02-17 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 25,000 @ $0 · Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-06-06 | 4 | IO Biotech, Inc. (IOBT) | Grant/award (A): 35,144 (derivative) @ $0 | EDGAR |
| 2025-02-10 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 171,000 (derivative) @ $0 | EDGAR |
| 2024-10-22 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 816 @ $2.48 · Sale (S): 816 @ $30.00 · Option exercise (M): 816 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Kura Oncology, Inc. (KURA) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | IO Biotech, Inc. (IOBT) | Grant/award (A): 45,642 (derivative) @ $0 | EDGAR |
| 2024-04-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Option exercise (M): 20,000 @ $2.48 · Sale (S): 20,000 @ $25.07 · Option exercise (M): 20,000 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Enliven Therapeutics, Inc. (ELVN) | Grant/award (A): 185,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1701247 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →